Kennedy Capital Management, Inc. Tcr2 Therapeutics Inc. Transaction History

Kennedy Capital Management, Inc.

  • $4.27 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
SELL
$0.83 - $1.44 $15 - $27
-19 Reduced 0.02%
120,389 $120,000
Q3 2022

Nov 14, 2022
SELL
$1.86 - $3.75 $414 - $836
-223 Reduced 0.18%
120,408 $217,000
Q2 2022

Aug 10, 2022
SELL
$2.11 - $2.94 $2,443 - $3,404
-1,158 Reduced 0.95%
120,631 $350,000
Q1 2022

May 16, 2022
BUY
$2.4 - $4.71 $292,293 - $573,626
121,789 New
121,789 $336,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Kennedy Capital Management, Inc. Portfolio

Follow Kennedy Capital Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Kennedy Capital Management, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email